Literature DB >> 32092362

Amorphous solid dispersions containing residual crystallinity: Influence of seed properties and polymer adsorption on dissolution performance.

Dana E Moseson1, Andrew S Parker2, Stephen P Beaudoin2, Lynne S Taylor3.   

Abstract

The solubility advantage of amorphous solid dispersions (ASDs) is contingent upon supersaturation being generated and maintained. If crystals are present within an ASD, these crystals directly result in lost solubility advantage, and may also seed crystal growth leading to desupersaturation. The goal of this study was to evaluate the impact of residual crystals on ASD supersaturation profiles. Indomethacin-copovidone (PVPVA) ASDs with different levels of residual crystallinity were manufactured by hot melt extrusion (HME). PVPVA at 5 and 50 µg/mL was found to be a highly effective nucleation and crystal growth inhibitor of indomethacin at high supersaturation. Evidence of polymer adsorption onto indomethacin crystals was observed by atomic force microscopy and scanning electron microscopy. HME ASDs containing 0-25% residual crystallinity demonstrated lost solubility advantage, along with minimal desupersaturation during non-sink dissolution testing. While bulk seeds did not properly represent the impact of residual crystals, extensive polymer adsorption onto residual seed crystals resulted in poisoned crystal growth, limiting the potential dissolution performance consequences. Several risk factors related to the presence of residual crystallinity were identified: polymeric crystal growth inhibition effectiveness, seed properties, and supersaturation conditions.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphous solid dispersion; Crystal growth; Non-sink dissolution; Polymer adsorption; Residual crystallinity; Supersaturation

Mesh:

Substances:

Year:  2020        PMID: 32092362     DOI: 10.1016/j.ejps.2020.105276

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

1.  pH-Dependent supersaturation from amorphous solid dispersions of weakly basic drugs.

Authors:  Bo Wang; Matthew J Nethercott; Akshay Narula; Michael Hanrahan; Shanming Kuang; Robert M Wenslow; Na Li
Journal:  Pharm Res       Date:  2021-12-10       Impact factor: 4.200

2.  Rational Fabrication of Folate-Conjugated Zein/Soy Lecithin/Carboxymethyl Chitosan Core-Shell Nanoparticles for Delivery of Docetaxel.

Authors:  Zhenyao Wu; Jie Li; Xin Zhang; Yangjia Li; Dongwei Wei; Lichang Tang; Shiming Deng; Guijin Liu
Journal:  ACS Omega       Date:  2022-04-07

3.  Benchmarking the Solubility Enhancement and Storage Stability of Amorphous Drug-Polyelectrolyte Nanoplex against Co-Amorphous Formulation of the Same Drug.

Authors:  Li Ming Lim; Jin-Won Park; Kunn Hadinoto
Journal:  Pharmaceutics       Date:  2022-05-02       Impact factor: 6.525

Review 4.  Overview of Extensively Employed Polymeric Carriers in Solid Dispersion Technology.

Authors:  Athira R Nair; Yarlagadda Dani Lakshman; Vullendula Sai Krishna Anand; K S Navya Sree; Krishnamurthy Bhat; Swapnil J Dengale
Journal:  AAPS PharmSciTech       Date:  2020-11-08       Impact factor: 3.246

5.  Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.

Authors:  Daniel A Davis; Dave A Miller; Supawan Santitewagun; J Axel Zeitler; Yongchao Su; Robert O Williams
Journal:  Int J Pharm X       Date:  2021-07-17

6.  Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for more robust release profiles.

Authors:  Tu Van Duong; Hanh Thuy Nguyen; Lynne S Taylor
Journal:  Eur J Pharm Biopharm       Date:  2022-04-09       Impact factor: 5.589

Review 7.  Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products.

Authors:  Palpandi Pandi; Raviteja Bulusu; Nagavendra Kommineni; Wahid Khan; Mandip Singh
Journal:  Int J Pharm       Date:  2020-06-18       Impact factor: 5.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.